Faculty profile
Joanne Liutkus
Back to facultyResearch
Research areas are derived from OpenAlex topics of their publications.
18 publications.
Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial
McInnes N, Hall S, Lochnan HA, Harris SB, Punthakee Z, Sigal RJ, Hramiak I, Azharuddin M, Liutkus JF, Yale J
Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups
Yale J-F, Bodholdt U, Catarig A-M, Catrina S, Clark A, Ekberg NR, Erhan U, Holmes P, Knudsen ST, Liutkus J
Use of once‐weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study
Yale J, Catarig A, Grau K, Harris S, Klimek‐Abercrombie A, Rabasa‐Lhoret R, Reardon L, Woo V, Liutkus J
Evaluating the Effectiveness of Switching to Insulin Degludec from Other Basal Insulins in a Real-World Canadian Population with Type 1 or Type 2 Diabetes: The CAN-TREAT Study
Harris SB, Ajala O, Bari B, Liutkus J, Hahn J, Martyn O, Zwicker D
677-P: Remission of Type 2 Diabetes following Intensive Treatment with Insulin Glargine, Lixisenatide, Metformin, and Lifestyle Approaches: Results of a Multicenter Randomized Controlled Trial
MCINNES N, HALL S, LOCHNAN HA, HARRIS SB, PUNTHAKEE Z, SIGAL RJ, HRAMIAK I, AZHARUDDIN M, LIUTKUS JF, YALE J-F
Patients reaching treatment targets with once-weekly semaglutide in real-world practice: pooled analysis of four SURE studies
Rudofsky G, Bodholdt U, Catarig A-M, Ekberg NR, Erhan U, Liutkus JF, Tariq M, Holmes P
64 - Real-World Use of Once-Weekly Semaglutide in Patients With Type 2 Diabetes: Results From SURE Canada
Yale J-F, Catarig A-M, Erhan U, Grau K, Klimek-Abercrombie A, Reardon L, Rabasa-Lhoret R, Woo V, Liutkus J
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial
Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, Araki E, Lind M, Bain SC, Jabbour S, Arya N
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP
Frequent collaborators
14Zubin Punthakee
Medicine
3 shared papers, latest 2023
Natalia McInnes
Medicine
2 shared papers, latest 2023
Stephen Walter
Health Research Methods, Evidence, and Impact
2 shared papers, latest 1997
Hertzel Gerstein
Medicine
2 shared papers, latest 2023
Diana Sherifali
Nursing
2 shared papers, latest 2023
Cathy Risdon
Family Medicine
2 shared papers, latest 1997
Researchers with similar interests
Hertzel Gerstein
Medicine
Diabetes Treatment and Management, Diabetes Management and Research
Natalia McInnes
Medicine
Diabetes Treatment and Management, Diabetes Management and Research
Zubin Punthakee
Medicine
Diabetes Treatment and Management, Diabetes Management and Research
Diana Sherifali
Nursing
Diabetes Management and Research, Diabetes Treatment and Management
Manoela Braga
Medicine
Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer
Upender Mehan
Family Medicine
Diabetes Management and Research, Diabetes, Cardiovascular Risks, and Lipoproteins
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.